Prognostic Groups of Visani et al in Myelofibrosis with Myeloid Metaplasia

Description

Visani et al developed a simple system for predicting survival in patients with myelofibrosis with myeloid metaplasia. This can be helpful in identifying patients who might benefit from more intense chemotherapy.

Parameters used for evaluating patients:

(1) percent of neutrophil precursors in the peripheral blood

(2) hemoglobin

Percent WBC Precursors in Peripheral Blood at the Time of Initial Diagnosis	Hemoglobin	Group
< 10%	>= 10 g/dL	I
< 10%	< 10%	II
>= 10%	NA	III

where:

• percent WBC precursors = (percent blasts) + (percent promyelocytes) + (percent myelocytes)

• The original paper had only > and <; the = are added as seems appropriate.

Group	Risk	Median Survival
I	good	81 months
II	intermediate	39 months
III	high	31 months

Other factors identified to be associated with prognosis:

(1) length of time between onset of symptoms and diagnosis (< 13 months associated with shorter survival)

(2) leukocyte count (WBC count > 12,000 per µL associated with shorter survival)

To read more or access our algorithms and calculators, please log in or register.

Description

Specialty

ICD-10